论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Kumar R, Yu F, Zhen YH, Li B, Wang J, Yang Y, Ge HX, Hu P, Xiu J
Received 13 December 2016
Accepted for publication 27 May 2017
Published 13 July 2017 Volume 2017:10 Pages 3453—3465
DOI https://doi.org/10.2147/OTT.S130131
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Ashok Kumar Pandurangan
Peer reviewer comments 3
Editor who approved publication: Dr Faris Farassati
Background: Adoptive T cell therapy has been proven to be a promising modality
for the treatment of cancer patients in recent years. However, the increased
expression of inhibitory receptors could negatively regulate the function and
persistence of transferred T cells which mediates T cell anergy, exhaustion,
and tumor regression. In this study, we investigated increased cytotoxic
activity after the blockade of PD-1 for effective immunotherapy.
Methods: The cytotoxic function of expanded CD8+ CTLs and interactions with tumor cells
investigated after blocking of PD-1. Ex vivo expanded CD8+ CTLs were co-cultured with mismatch repair
(MMR) stable or deficient (high microsatellite instability [MSI-H]) EpCAM+ tumor cells. The levels of IFN-γ and GrB were
detected by enzyme-linked immunosorbent spot assay. Flow cytometry and confocal
microscopy were used to assess CD107a mobilization, cytosolic uptake, and cell
migration.
Results: A dramatic increase in PD-1 expression on the
surface of CD8+ CTLs during ex vivo
expansion was observed. PD-1 level was downregulated by approximately 40% after
incubation of the CD8+ CTLs with monoclonal
antibody which enhanced the secretion of IFN-γ, GrB, and CD107a. Additionally,
PD-1 blockade enhanced cell migration and cytosolic exchange between CD8+ CTLs and MMR deficient (MSI-H) EpCAM+PD-L1+ tumor
cells.
Conclusion: The blockade of PD-1 enhanced the cytotoxic efficacy
of CD8+ CTLs toward MMR deficient tumor cells. In
conclusion, we propose that blocking of PD-1 during the expansion of CD8+ CTLs
may improve the clinical efficacy of cell-based adoptive immunotherapy.
Keywords: PD-1, CTLs,
MSI-H, EpCAM+PD-L1+, cancer
immunotherapy